MYC and Hepatic fibrosis: Through a series of in vivo and in vitro experiments, it can be concluded that eupatilin significantly relieved hepatic fibrosis and HSC activation by inhibiting the EMT process and proliferation of HSCs via down-regulating the mRNA levels of downstream targets of the β-catenin pathway, including PAI-1, cyclinD1, and c-Myc (Figure 8).